{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T23:25:37Z","timestamp":1795130737485,"version":"4.10.3"},"reference-count":43,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"45","license":[{"start":{"date-parts":[[2023,11,10]],"date-time":"2023-11-10T00:00:00Z","timestamp":1699574400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,11,10]]},"abstract":"<jats:p>This study evaluated the therapeutic effects and toxic reactions of combining transcatheter arterial chemoembolization (TACE) and intensity-modulated radiotherapy (IMRT) with sorafenib for the treatment of advanced hepatocellular carcinoma (HCC) patients with macrovascular invasion (MVI). We retrospectively analyzed the clinical data of 82 HCC patients with MVI, among whom 35 were treated with TACE plus IMRT alone, and 47 were treated with the combined therapy of TACE, IMRT, and sorafenib. The progression-free survival (PFS), overall survival (OS), and adverse events were assessed. The baseline characteristics were comparable between the 2 groups (all <jats:italic toggle=\"yes\">P<\/jats:italic> &gt; .05). In the TACE plus IMRT plus sorafenib group, the median PFS was 17.2 months (95% confidence interval, 14.1\u201319.9), significantly longer than the 9.4 months (95% confidence interval, 6.8\u201311.2) observed in the TACE plus IMRT group (<jats:italic toggle=\"yes\">P<\/jats:italic> &lt; .001). Additionally, patients treated with the TACE plus IMRT plus sorafenib showed a longer median OS than those treated with TACE plus IMRT alone (24.1 vs 17.3 months; <jats:italic toggle=\"yes\">P<\/jats:italic> &lt; .001). The occurrence rates of grade 1 to 2 hand-foot syndrome, other skin reactions, diarrhea, and hair loss were higher in the TACE plus IMRT plus sorafenib group (all <jats:italic toggle=\"yes\">P<\/jats:italic> &lt; .05). There were no grade 4 or higher adverse events in either group. The combination of TACE plus IMRT with sorafenib provided substantial clinical benefits in the treatment of HCC patients with MVI, increasing the tumor response rate and prolonging both PFS and OS. This approach demonstrated a tolerable and manageable safety profile.<\/jats:p>","DOI":"10.1097\/md.0000000000035713","type":"journal-article","created":{"date-parts":[[2023,11,10]],"date-time":"2023-11-10T19:04:05Z","timestamp":1699643045000},"page":"e35713","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":7,"title":["Combination treatment of transcatheter arterial chemoembolization, intensity-modulated radiotherapy, and sorafenib for hepatocellular carcinoma with macrovascular invasion"],"prefix":"10.1097","volume":"102","author":[{"given":"Dan","family":"Yang","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, 3201 Hospital, Hanzhong, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaojiao","family":"Du","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, 3201 Hospital, Hanzhong, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weijie","family":"Nie","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, 3201 Hospital, Hanzhong, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaozhi","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, 3201 Hospital, Hanzhong, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-0032-731X","authenticated-orcid":false,"given":"Zhufang","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, 3201 Hospital, Hanzhong, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"541","DOI":"10.6004\/jnccn.2021.0022","article-title":"Hepatobiliary cancers, version 22021, NCCN clinical practice guidelines in oncology.","volume":"19","author":"Benson","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"key":"R2-20250504","first-page":"4197","article-title":"Magnetic resonance imaging evaluation of characteristics of vascular invasion in intermediate and advanced hepatic alveolar echinococcosis.","volume":"17","author":"Yang","year":"2019","journal-title":"Exp Ther Med"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"843589","DOI":"10.3389\/fonc.2022.843589","article-title":"Nomograms for predicting hepatocellular carcinoma recurrence and overall postoperative patient survival.","volume":"12","author":"Ma","year":"2022","journal-title":"Front Oncol"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"E20","DOI":"10.1111\/ans.14708","article-title":"Nomogram predicting survival of hepatocellular carcinoma with portal vein tumour thrombus after curative resection.","volume":"89","author":"Hu","year":"2019","journal-title":"ANZ J Surg"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s12935-021-01790-6","article-title":"The effects of several postoperative adjuvant therapies for hepatocellular carcinoma patients with microvascular invasion after curative resection: a systematic review and meta-analysis.","volume":"21","author":"Yang","year":"2021","journal-title":"Cancer Cell Int"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"541","DOI":"10.2147\/OTT.S187357","article-title":"Should we apply sorafenib in hepatocellular carcinoma patients with microvascular invasion after curative hepatectomy?","volume":"12","author":"Huang","year":"2019","journal-title":"Onco Targets Ther"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"1215745","DOI":"10.3389\/fimmu.2023.1215745","article-title":"Development and validation of prognostic risk prediction models for hepatocellular carcinoma patients treated with immune checkpoint inhibitors based on a systematic review and meta-analysis of 47 cohorts.","volume":"14","author":"Ma","year":"2023","journal-title":"Front Immunol"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"3948","DOI":"10.21037\/qims-22-1011","article-title":"Development of a magnetic resonance imaging-derived radiomics model to predict microvascular invasion in patients with hepatocellular carcinoma.","volume":"13","author":"Liu","year":"2023","journal-title":"Quant Imaging Med Surg"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.dld.2018.11.004","article-title":"Phase I\/II trial of helical IMRT-based stereotactic body radiotherapy for hepatocellular carcinoma.","volume":"51","author":"Kim","year":"2019","journal-title":"Dig Liver Dis"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.3389\/fonc.2019.01065","article-title":"Safety and efficacy of transcatheter arterial chemoembolization plus radiotherapy combined with sorafenib in hepatocellular carcinoma showing macrovascular invasion.","volume":"9","author":"Zhao","year":"2019","journal-title":"Front Oncol"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.radonc.2019.05.006","article-title":"Postoperative adjuvant IMRT for patients with HCC and portal vein tumor thrombus: an open-label randomized controlled trial.","volume":"140","author":"Sun","year":"2019","journal-title":"Radiother Oncol"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1186\/s12967-023-04386-y","article-title":"Advances in radiotherapy and immunity in hepatocellular carcinoma.","volume":"21","author":"Yang","year":"2023","journal-title":"J Transl Med"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1186\/s12957-023-03098-3","article-title":"Efficacy of transarterial therapy combined with first-line tyrosine kinase inhibitors for unresectable hepatocellular carcinoma: a network meta-analysis.","volume":"21","author":"Hu","year":"2023","journal-title":"World J Surg Oncol"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"3782","DOI":"10.1002\/cncr.33677","article-title":"Transarterial chemoembolization plus lenvatinib versus transarterial chemoembolization plus sorafenib as first-line treatment for hepatocellular carcinoma with portal vein tumor thrombus: a prospective randomized study.","volume":"127","author":"Ding","year":"2021","journal-title":"Cancer"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"2242384","DOI":"10.1080\/07853890.2023.2242384","article-title":"Molecular targeted therapy and immunotherapy in advanced hepatocellular carcinoma: a systematic review and Bayesian network meta-analysis based on randomized controlled trials.","volume":"55","author":"Zhang","year":"2023","journal-title":"Ann Med"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/j.jhep.2019.08.006","article-title":"Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma.","volume":"71","author":"Ricke","year":"2019","journal-title":"J Hepatol"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"e3789","DOI":"10.1097\/MD.0000000000003789","article-title":"Efficacy and safety of intensity-modulated radiotherapy following transarterial chemoembolization in patients with unresectable hepatocellular carcinoma.","volume":"95","author":"Zhang","year":"2016","journal-title":"Medicine (Baltim)"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1111\/liv.12857","article-title":"Survival benefit with IMRT following narrow-margin hepatectomy in patients with hepatocellular carcinoma close to major vessels.","volume":"35","author":"Wang","year":"2015","journal-title":"Liver Int"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1016\/j.jhep.2016.07.020","article-title":"Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: The GIDEON study.","volume":"65","author":"Marrero","year":"2016","journal-title":"J Hepatol"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1055\/s-0030-1247132","article-title":"Modified RECIST (mRECIST) assessment for hepatocellular carcinoma.","volume":"30","author":"Lencioni","year":"2010","journal-title":"Semin Liver Dis"},{"key":"R21-20250504","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.semradonc.2018.06.007","article-title":"Radiation-induced liver disease and modern radiotherapy.","volume":"28","author":"Koay","year":"2018","journal-title":"Semin Radiat Oncol"},{"key":"R22-20250504","doi-asserted-by":"crossref","first-page":"3002","DOI":"10.1200\/JCO.21.00163","article-title":"Donafenib versus sorafenib in first-line treatment of unresectable or metastatic hepatocellular carcinoma: a randomized, open-label, parallel-controlled phase II\u2013III trial.","volume":"39","author":"Qin","year":"2021","journal-title":"J Clin Oncol"},{"key":"R23-20250504","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1016\/j.ejca.2011.12.006","article-title":"Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: subset analyses of the phase III Sorafenib Asia-Pacific trial.","volume":"48","author":"Cheng","year":"2012","journal-title":"Eur J Cancer"},{"key":"R24-20250504","doi-asserted-by":"crossref","first-page":"300060520946872","DOI":"10.1177\/0300060520946872","article-title":"Sorafenib in the treatment of patients with hepatocellular carcinoma (HCC) and microvascular infiltration: a systematic review and meta-analysis.","volume":"48","author":"Gu","year":"2020","journal-title":"J Int Med Res"},{"key":"R25-20250504","doi-asserted-by":"crossref","first-page":"3789","DOI":"10.3390\/cancers15153789","article-title":"Efficacy of the combination of systemic sequential therapy and locoregional therapy in the long-term survival of patients with BCLC stage C hepatocellular carcinoma.","volume":"15","author":"Kawamura","year":"2023","journal-title":"Cancers (Basel)"},{"key":"R26-20250504","doi-asserted-by":"crossref","first-page":"521","DOI":"10.3350\/cmh.2023.0202","article-title":"Transarterial chemoembolization for hepatocellular carcinoma: 2023 expert consensus-based practical recommendations of the Korean Liver Cancer Association.","volume":"29","author":"Cho","year":"2023","journal-title":"Clin Mol Hepatol"},{"key":"R27-20250504","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/s12957-023-02961-7","article-title":"Transarterial chemoembolization (TACE) plus tyrosine kinase inhibitors versus TACE in patients with hepatocellular carcinoma: a systematic review and meta-analysis.","volume":"21","author":"Duan","year":"2023","journal-title":"World J Surg Oncol"},{"key":"R28-20250504","doi-asserted-by":"crossref","first-page":"e77240","DOI":"10.1371\/journal.pone.0077240","article-title":"Efficacy of sorafenib monotherapy versus sorafenib-based loco-regional treatments in advanced hepatocellular carcinoma.","volume":"8","author":"Lee","year":"2013","journal-title":"PLoS One"},{"key":"R29-20250504","first-page":"261","article-title":"Recent therapeutics in hepatocellular carcinoma.","volume":"13","author":"Fan","year":"2023","journal-title":"Am J Cancer Res"},{"key":"R30-20250504","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1007\/s00432-021-03788-z","article-title":"MRI-guided radiotherapy for PVTT in HCC patients: evaluation of the efficacy and safety.","volume":"148","author":"Lee","year":"2022","journal-title":"J Cancer Res Clin Oncol"},{"key":"R31-20250504","doi-asserted-by":"crossref","first-page":"930868","DOI":"10.3389\/fonc.2022.930868","article-title":"Efficacy of transarterial chemoembolization monotherapy or combination conversion therapy in unresectable hepatocellular carcinoma: a systematic review and meta-analysis.","volume":"12","author":"Li","year":"2022","journal-title":"Front Oncol"},{"key":"R32-20250504","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1007\/s11604-019-00868-6","article-title":"Hepatocellular carcinoma and macrovascular tumor thrombosis: treatment outcomes and prognostic factors for survival.","volume":"37","author":"Kim","year":"2019","journal-title":"Jpn J Radiol"},{"key":"R33-20250504","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s12876-018-0849-0","article-title":"Transarterial chemoembolization plus sorafenib for the management of unresectable hepatocellular carcinoma: a systematic review and meta-analysis.","volume":"18","author":"Li","year":"2018","journal-title":"BMC Gastroenterol"},{"key":"R34-20250504","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.jvir.2014.10.019","article-title":"Comparison of chemoembolization with and without radiation therapy and sorafenib for advanced hepatocellular carcinoma with portal vein tumor thrombosis: a propensity score analysis.","volume":"26","author":"Kim","year":"2015","journal-title":"J Vasc Interv Radiol"},{"key":"R35-20250504","doi-asserted-by":"crossref","first-page":"1074793","DOI":"10.3389\/fonc.2023.1074793","article-title":"Transarterial chemoembolization combined with lenvatinib versus transarterial chemoembolization combined with sorafenib for unresectable hepatocellular carcinoma: a systematic review and meta-analysis.","volume":"13","author":"Liu","year":"2023","journal-title":"Front Oncol"},{"key":"R36-20250504","doi-asserted-by":"crossref","first-page":"148","DOI":"10.5582\/bst.2021.01173","article-title":"The multidisciplinary management of hepatocellular carcinoma with portal vein tumor thrombus.","volume":"15","author":"Qiu","year":"2021","journal-title":"Biosci Trends"},{"key":"R37-20250504","doi-asserted-by":"crossref","first-page":"4360","DOI":"10.3748\/wjg.v25.i31.4360","article-title":"Treatment of hepatocellular carcinoma in patients with portal vein tumor thrombosis: beyond the known frontiers.","volume":"25","author":"Cerrito","year":"2019","journal-title":"World J Gastroenterol"},{"key":"R38-20250504","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1001\/jamaoncol.2015.2189","article-title":"Transcatheter arterial chemoembolization plus radiotherapy compared with chemoembolization alone for hepatocellular carcinoma: a systematic review and meta-analysis.","volume":"1","author":"Huo","year":"2015","journal-title":"JAMA Oncol"},{"key":"R39-20250504","doi-asserted-by":"crossref","first-page":"531","DOI":"10.5152\/dir.2020.19569","article-title":"Hepatocellular carcinoma with macrovascular invasion: multimodality imaging features for the diagnosis.","volume":"26","author":"Cannella","year":"2020","journal-title":"Diagn Interv Radiol"},{"key":"R40-20250504","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1002\/jcp.27324","article-title":"Comprehensive treatments for hepatocellular carcinoma with portal vein tumor thrombosis.","volume":"234","author":"Wang","year":"2019","journal-title":"J Cell Physiol"},{"key":"R41-20250504","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.radonc.2017.11.013","article-title":"Comparison of radiation therapy modalities for hepatocellular carcinoma with portal vein thrombosis: a meta-analysis and systematic review.","volume":"129","author":"Rim","year":"2018","journal-title":"Radiother Oncol"},{"key":"R42-20250504","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.radonc.2019.12.004","article-title":"Comparisons between radiofrequency ablation and stereotactic body radiotherapy for liver malignancies: Meta-analyses and a systematic review.","volume":"145","author":"Lee","year":"2020","journal-title":"Radiother Oncol"},{"key":"R43-20250504","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1080\/17512433.2019.1689122","article-title":"Sorafenib-associated hand-foot skin reaction: practical advice on diagnosis, mechanism, prevention, and management.","volume":"12","author":"Ai","year":"2019","journal-title":"Expert Rev Clin Pharmacol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000035713","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T02:31:18Z","timestamp":1746325878000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000035713"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,10]]},"references-count":43,"journal-issue":{"issue":"45","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000035713","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,10]]}}}